3. 脊髄性筋萎縮症 Spinal muscular atrophy Clinical trials / Disease details


臨床試験数 : 237 薬物数 : 123 - (DrugBank : 29) / 標的遺伝子数 : 51 - 標的パスウェイ数 : 75

  
1 trial found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT05337553
(ClinicalTrials.gov)
July 6, 202214/4/2022A Study to Evaluate the Efficacy and Safety of Taldefgrobep Alfa in Participants With Spinal Muscular AtrophyA Randomized, Double-Blind, Placebo-Controlled, Study to Evaluate the Efficacy and Safety of Taldefgrobep Alfa in Ambulatory and Non-Ambulatory Participants With Spinal Muscular Atrophy With Open-Label ExtensionSpinal Muscular Atrophy;Neuromuscular Diseases;SMADrug: taldefgrobep alfa;Drug: PlaceboBiohaven Pharmaceuticals, Inc.NULLRecruiting4 Years21 YearsAll225Phase 3United States;Belgium;France;Germany;Italy;Netherlands;Poland;Spain;United Kingdom